GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Provided By GlobeNewswire
Last update: Sep 26, 2024
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Dr. Jeffrey Miller, MD1, from the University of Minnesota Medical School2 and GT Biopharma’s Consulting Senior Medical Director, will participate in a panel discussion on innovative therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York, NY. Company management will also be participating in 1x1 meetings during the event.
NASDAQ:GTBP (3/7/2025, 8:00:01 PM)
2.44
+0.07 (+2.95%)
Find more stocks in the Stock Screener
GTBP Latest News and Analysis
13 days ago - ChartmillTraders are paying attention to the gapping stocks in Tuesday's session.The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
13 days ago - ChartmillWhat's going on in today's pre-market sessionLet's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
